Arterial hypertension (AH) is widespread among the adult population and is one of the main and independent risk factors for the development of cardiovascular, cerebrovascular and renal diseases. Taking into account the high prevalence of comorbid pathology and the associated high cardiovascular risk, the choice of antihypertensive drugs (AHDs) is particularly important. The current dominant strategy for the treatment of AH is the use of fixed combinations of antihypertensive drugs, which increase patient adherence to treatment and ultimately increase the frequency of achieving the target blood pressure (BP) level. Valsartan and amlodipine are drugs with proven effectiveness and safety and can act as first-line drugs for the treatment of AH in patients with comorbid pathology. The use of the fixed combination of valsartan/amlodipine is associated with a more pronounced absolute reduction in blood pressure and fewer cases of antihypertensive discontinuation due to side effects and non-compliance with treatment compared with the use of individual drugs in monotherapy. The high antihypertensive effectiveness of the fixed combination of valsartan/amlodipine has been shown in patients with broncho-obstructive diseases and smokers. Valsartan in combination with amlodipine has a positive effect on the course of diabetic nephropathy, which allows us to recommend this combination as the first line of antihypertensive therapy for patients with this pathology. The fixed combination of valsartan/amlodipine reduces the risks of cardiovascular complications and improves the long-term prognosis of hypertensive patients.

Keywords: angiotensin receptor blockers, antihypertensive therapy, calcium channel blockers, arterial hypertension